Charlene Lancaster, PhD | Mar 12, 2024 | 4 min read
Using a circuit-based system, scientists determined the ideal transcription factor levels to promote the successful reprogramming of fibroblasts into induced pluripotent stem cells.
Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.